PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Comparing Methods for Estimating Direct Costs of Adverse Drug Events.

Abstract To estimate how direct health care costs resulting from adverse drug events (ADEs) and cost distribution are affected by methodological decisions regarding identification of ADEs, assigning relevant resource use to ADEs, and estimating costs for the assigned resources.
PMID
Related Publications

Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults.

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study.

Costs of adverse drug events in German hospitals--a microcosting study.

Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults.

Authors

Mayor MeshTerms
Keywords

adverse drug event

health care costs

medical records

pharmacoeconomics

Journal Title value in health : the journal of the international society for pharmacoeconomics and outcomes research
Publication Year Start




PMID- 29241889
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 20
IP  - 10
DP  - 2017 Dec
TI  - Comparing Methods for Estimating Direct Costs of Adverse Drug Events.
PG  - 1299-1310
LID - S1098-3015(17)30310-8 [pii]
LID - 10.1016/j.jval.2017.06.007 [doi]
AB  - OBJECTIVES: To estimate how direct health care costs resulting from adverse drug 
      events (ADEs) and cost distribution are affected by methodological decisions
      regarding identification of ADEs, assigning relevant resource use to ADEs, and
      estimating costs for the assigned resources. METHODS: ADEs were identified from
      medical records and diagnostic codes for a random sample of 4970 Swedish adults
      during a 3-month study period in 2008 and were assessed for causality. Results
      were compared for five cost evaluation methods, including different methods for
      identifying ADEs, assigning resource use to ADEs, and for estimating costs for
      the assigned resources (resource use method, proportion of registered cost
      method, unit cost method, diagnostic code method, and main diagnosis method).
      Different levels of causality for ADEs and ADEs' contribution to health care
      resource use were considered. RESULTS: Using the five methods, the maximum
      estimated overall direct health care costs resulting from ADEs ranged from
      Sk10,000 (Sk = Swedish krona; ~euro1,500 in 2016 values) using the diagnostic
      code method to more than Sk3,000,000 (~euro414,000) using the unit cost method in
      our study population. The most conservative definitions for ADEs' contribution to
      health care resource use and the causality of ADEs resulted in average costs per 
      patient ranging from Sk0 using the diagnostic code method to Sk4066 (~euro500)
      using the unit cost method. CONCLUSIONS: The estimated costs resulting from ADEs 
      varied considerably depending on the methodological choices. The results indicate
      that costs for ADEs need to be identified through medical record review and by
      using detailed unit cost data.
CI  - Copyright (c) 2017 International Society for Pharmacoeconomics and Outcomes
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Gyllensten, Hanna
AU  - Gyllensten H
AD  - Nordic School of Public Health NHV, Gothenburg, Sweden; Institute of Health and
      Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
      Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska
      Institutet, Stockholm, Sweden. Electronic address: [email protected]
FAU - Jonsson, Anna K
AU  - Jonsson AK
AD  - National Board of Forensic Medicine, Department of Forensic Genetics and Forensic
      Toxicology, Linkoping, Sweden.
FAU - Hakkarainen, Katja M
AU  - Hakkarainen KM
AD  - Nordic School of Public Health NHV, Gothenburg, Sweden; EPID Research, Espoo,
      Finland.
FAU - Svensson, Staffan
AU  - Svensson S
AD  - Narhalsan Hjallbo Medical Centre, Angered, Sweden.
FAU - Hagg, Staffan
AU  - Hagg S
AD  - Department of Drug Research/Clinical Pharmacology, Faculty of Health Sciences,
      Linkoping University, Linkoping, Sweden; Futurum-Academy for Health and Care,
      Jonkoping County Council, Jonkoping, Sweden.
FAU - Rehnberg, Clas
AU  - Rehnberg C
AD  - Department of Learning, Informatics, Management and Ethics, Karolinska
      Institutet, Stockholm, Sweden.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170725
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Causality
MH  - Clinical Coding/*methods
MH  - Costs and Cost Analysis/*methods
MH  - Drug-Related Side Effects and Adverse Reactions/diagnosis/*economics
MH  - Female
MH  - Health Care Costs/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Medical Records/statistics & numerical data
MH  - Middle Aged
MH  - Sweden
MH  - Young Adult
OTO - NOTNLM
OT  - adverse drug event
OT  - health care costs
OT  - medical records
OT  - pharmacoeconomics
EDAT- 2017/12/16 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/12/16 06:00
PHST- 2016/07/15 00:00 [received]
PHST- 2017/05/29 00:00 [revised]
PHST- 2017/06/10 00:00 [accepted]
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S1098-3015(17)30310-8 [pii]
AID - 10.1016/j.jval.2017.06.007 [doi]
PST - ppublish
SO  - Value Health. 2017 Dec;20(10):1299-1310. doi: 10.1016/j.jval.2017.06.007. Epub
      2017 Jul 25.